<DOC>
	<DOCNO>NCT00061529</DOCNO>
	<brief_summary>The primary objective study compare safety efficacy Brimonidine Tartrate Ophthalmic Solution , 0.15 % patient open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>A Phase III Study Brimonidine Tartrate Ophthalmic Solution , 0.15 % Patients With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients race two ( 2 ) year age old either sex diagnose openangle glaucoma ( without pseudoexfoliation pigment dispersion component ) ocular hypertension</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>